The European Commission granted marketing approval Tuesday for Inflectra, a treatment for rheumatoid arthritis. The drug is a biosimilar monoclonal antibody therapy and an alternative to the locally developed Remicade which is used for inflammatory conditions like arthritis. Remicade was developed by Malvern, Pa.-based Centocor in the 1990s.
Help employers find you! Check out all the jobs and post your resume.
